Brendan Saloner1, Kenneth B Stoller1, Colleen L Barry1. 1. Dr. Saloner and Dr. Barry are with the Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore (e-mail: bsaloner@jhu.edu ). Dr. Stoller is with Johns Hopkins University School of Medicine, Baltimore.
Abstract
OBJECTIVE: This study examined differences in opioid agonist therapy (OAT) utilization among Medicaid-enrolled adults receiving public-sector opioid use disorder treatment in states with Medicaid coverage of methadone maintenance, states with block grant funding only, and states without public coverage of methadone. METHODS: Person-level treatment admission data, which included information on reason for treatment and use of OAT from 36 states were linked to state-level Medicaid policies collected in a 50-state survey. Probabilities of OAT use among Medicaid enrollees in opioid addiction treatment were calculated, with adjustment for demographic characteristics and patterns of substance use. RESULTS: In adjusted analysis, 45.0% of Medicaid-enrolled individuals in opioid addiction treatment in states with Medicaid coverage for methadone maintenance used OAT, compared with 30.1% in states with block grant coverage only and 17.0% in states with no coverage. Differences were widest in nonintensive outpatient settings. CONCLUSIONS: Medicaid methadone maintenance coverage is critical for encouraging OAT among individuals with opioid use disorders.
OBJECTIVE: This study examined differences in opioid agonist therapy (OAT) utilization among Medicaid-enrolled adults receiving public-sector opioid use disorder treatment in states with Medicaid coverage of methadone maintenance, states with block grant funding only, and states without public coverage of methadone. METHODS:Person-level treatment admission data, which included information on reason for treatment and use of OAT from 36 states were linked to state-level Medicaid policies collected in a 50-state survey. Probabilities of OAT use among Medicaid enrollees in opioid addiction treatment were calculated, with adjustment for demographic characteristics and patterns of substance use. RESULTS: In adjusted analysis, 45.0% of Medicaid-enrolled individuals in opioid addiction treatment in states with Medicaid coverage for methadone maintenance used OAT, compared with 30.1% in states with block grant coverage only and 17.0% in states with no coverage. Differences were widest in nonintensive outpatient settings. CONCLUSIONS: Medicaid methadone maintenance coverage is critical for encouraging OAT among individuals with opioid use disorders.
Authors: Scott E Hadland; J Frank Wharam; Mark A Schuster; Fang Zhang; Jeffrey H Samet; Marc R Larochelle Journal: JAMA Pediatr Date: 2017-08-01 Impact factor: 16.193
Authors: Kayla N Tormohlen; Noa Krawczyk; Kenneth A Feder; Kira E Riehm; Rosa M Crum; Ramin Mojtabai Journal: Health Serv Res Date: 2019-12-29 Impact factor: 3.402
Authors: Anjalee Sharma; Sharon M Kelly; Shannon Gwin Mitchell; Jan Gryczynski; Kevin E O'Grady; Robert P Schwartz Journal: Curr Psychiatry Rep Date: 2017-06 Impact factor: 5.285